Quest for the right Drug
בוסטריקס פוליו BOOSTRIX POLIO (DIPHTHERIA TOXOID, FILAMENTOUS HAEMAGGLUTININ (FHA), INACTIVATED POLIO VIRUS (IPV) TYPE 1, INACTIVATED POLIO VIRUS (IPV) TYPE 2, INACTIVATED POLIO VIRUS (IPV) TYPE 3, PERTACTIN (PRN OR 69 KDA OMP), PERTUSSIS TOXOID VACCINE, TETANUS TOXOID)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-שרירי : I.M
צורת מינון:
תרחיף להזרקה : SUSPENSION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Special Warning : אזהרת שימוש
4.4 Special warnings and precautions for use Vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events). If any of the following events are known to have occurred in temporal relation to receipt of pertussis- containing vaccine, the decision to give doses of pertussis-containing vaccines should be carefully considered: - Temperature of 40.0°C within 48 hours of vaccination, not due to another identifiable cause. - Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination. - Persistent, inconsolable crying lasting 3 hours, occurring within 48 hours of vaccination. - Convulsions with or without fever, occurring within 3 days of vaccination. There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks. As for any vaccination, the risk-benefit of immunising with Boostrix Polio or deferring this vaccination should be weighed carefully in a child suffering from a new onset or progression of a severe neurological disorder. As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine. Boostrix Polio should be administered with caution to subjects with thrombocytopenia (see section 4.3) or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. If in accordance with official recommendations, the vaccine may be administered subcutaneously to these subjects. With both routes of administration, firm pressure should be applied to the injection site (without rubbing) for at least two minutes. Boostrix Polio should in no circumstances be administered intravascularly. A history of febrile convulsions, a family history of convulsions and a family history of an adverse event following DTP vaccination do not constitute contraindications. Human Immunodeficiency Virus (HIV) infection is not considered as a contraindication. The expected immunological response may not be obtained after vaccination of immunosuppressed patients. Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. As with any vaccine, a protective immune response may not be elicited in all vaccinees. Excipients with known effect Boostrix Polio contains para-aminobenzoic acid. It may cause allergic reactions (possibly delayed), and exceptionally, bronchospasm. This medicine contains 0.0298 micrograms phenylalanine in each dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’. This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially ‘potassium- free’. Traceability In order to improve the traceability of biological medicinal products, the name of the administered product should be clearly recorded. It is recommended to record the batch number as well.
Effects on Driving
4.7 Effects on ability to drive and use machines The vaccine is unlikely to produce an effect on the ability to drive and use machines.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לצרכן
14.07.14 - עלון לצרכן 12.09.19 - עלון לצרכן 02.09.21 - עלון לצרכן עברית 11.10.22 - עלון לצרכן אנגלית 11.10.22 - עלון לצרכן עברית 11.10.22 - עלון לצרכן ערבית 13.12.22 - עלון לצרכן אנגלית 13.12.22 - עלון לצרכן עברית 13.12.22 - עלון לצרכן ערבית 24.01.24 - עלון לצרכן עברית 06.03.24 - עלון לצרכן עברית 10.03.24 - עלון לצרכן אנגלית 10.03.24 - עלון לצרכן ערבית 02.04.24 - עלון לצרכן עברית 06.06.24 - עלון לצרכן אנגלית 06.06.24 - עלון לצרכן עברית 06.06.24 - עלון לצרכן ערבית 04.12.11 - החמרה לעלון 02.09.21 - החמרה לעלון 02.04.24 - החמרה לעלון 20.09.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
בוסטריקס פוליו